CompletedNot Applicable

RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides

France20 participantsStarted 2004-05

Plain-language summary

The purpose of this study is to compare a 2 immunosuppressant regimen for the treatment of relapsing or refractory necrotizing antineutrophil cytoplasmic antibody (ANCA) associated vasculitides.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Systemic ANCA positive (+) vasculitides * Relapsing or refractory vasculitides, resistant to corticosteroids and reference immunosuppressant therapies * Age \>18 years old * Written informed consent Exclusion Criteria: * Newly diagnosed patient * Patient that had never received an immunosuppressant before to treat his/her vasculitis * Malignancy * Pregnancy

What they're measuring

Partial or complete remission of the vasculitides

Timeframe: one year

Trial details

NCT IDNCT00307593

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Wegener's Granulomatosis trials